JP Morgan Downgrades 10x Genomics to Neutral, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Rachel Vatnsdal has downgraded 10x Genomics (NASDAQ:TXG) from Overweight to Neutral and lowered the price target from $40 to $20.
July 18, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan analyst Rachel Vatnsdal downgraded 10x Genomics from Overweight to Neutral and reduced the price target from $40 to $20.
The downgrade from Overweight to Neutral and the significant reduction in the price target from $40 to $20 by a major financial institution like JP Morgan is likely to negatively impact investor sentiment and the stock price of 10x Genomics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100